BMYClinical Trials•businesswire•August 29, 2025 at 11:35 AM

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Sentiment:Neutral (45)

Summary

(NYSE:BMY) PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 29, 2025 by businesswire